BioCardia (BCDA) vs IN8bio (INAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioCardia (BCDA) has outperformed IN8bio (INAB) over the past year, losing 25.4% versus a loss of 42.7%. Over five years, BCDA leads with a -97.6% price change compared with -99.2% for INAB. BioCardia is the larger company by market cap ($16.0 million vs $13.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | INAB |
|---|---|---|
| Share price | $1.06 | $1.38 |
| Market cap | $16.05M | $13.60M |
| 1-day change | -2.75% | -1.43% |
| YTD return | -15.20% | -41.03% |
| 1-year return | -25.35% | -42.74% |
| 5-year return | -97.59% | -99.23% |
| EPS (TTM) | $-0.64 | $-1.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $2.73 |
| 52-week low | $0.75 | $0.88 |
| Distance from 52-week high | -41.11% | -49.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +1362.26% | +407.25% |
| Average volume | 282.05K | 58.36K |
| Shares outstanding | 15.14M | 9.86M |
| Employees | 17 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed INAB by 17.4 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Healthcare · Biotechnology · 18 employees
BCDA vs INAB FAQ
Which is bigger, BioCardia or IN8bio?
BioCardia (BCDA) is larger, with a market capitalization of $16.05M compared with $13.60M for IN8bio (INAB).
Which stock has performed better over the past year, BCDA or INAB?
BCDA returned -25.35% over the past 12 months, compared with -42.74% for INAB (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and IN8bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.